Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Jiangsu Recbio Technology Co Ltd
2179Current price
8.4 HKD
+0.26 HKD (+3.19%)
Last closed
8.39 HKD
Company
www.recbio.cn
ISIN
CNE1000057K9
Sector
Healthcare
Industry
Biotechnology
Exchange
Hong Kong Stock Exchange
Capitalization
3 930 923 096 HKD
Yield for 12 month
-28.21 %
1Y
3Y
5Y
10Y
15Y
2179
Jiangsu Recbio Technology Co., Ltd., a vaccine company, engages in the research, development, and commercialization of subunit vaccines in the People's Republic of China. The company is developing vaccines for the treatment of cervical cancer, and anal and genital warts, including REC603, a recombinant human papillomavirus (HPV) 9-valent vaccine that is in phase III clinical trial; REC601 and REC602 recombinant HPV bivalent vaccines, which are in phase I clinical trials; REC604a, a recombinant HPV quadrivalent vaccine that is in pre-clinical stage; and REC604b, a recombinant HPV 9-valent vaccine that is in pre-clinical stage. It also develops ReCOV, a recombinant COVID-19 vaccine candidate that is in Phase II/III trial; R520A, a messenger ribonucleic acid COVID-19 vaccine candidate that is in pre-clinical stage; REC610, a recombinant shingles vaccine that is in Phase l clinical trial; REC607, a virus vectored adult tuberculosis vaccine that is in pre-clinical stage; REC606, a recombinant adult tuberculosis vaccine that is in pre-clinical stage; REC617, a recombinant influenza quadrivalent vaccine that is in pre-clinical stage; and REC605, a recombinant hand-foot-mouth disease quadrivalent vaccine that is in pre-clinical stage. Jiangsu Recbio Technology Co., Ltd. was founded in 2011 and is headquartered in Taizhou, the People's Republic of China. Address: No. 888 Yaocheng Avenue, Taizhou, China
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
101.12 HKDP/E ratio
–Dividend Yield
–Current Year
–
Last Year
–
Current Quarter
–
Last Quarter
–
Current Year
–
Last Year
–
Current Quarter
–
Last Quarter
–
Key Figures 2179
1 year
3 years
5 years
10 years
EBITDA
-482 803 569 HKD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-15.8 %
PEG Ratio
–
Return On Equity TTM
-49.76 %
Wall Street Target Price
101.12 HKD
Revenue TTM
43 449 007 HKD
Book Value
1.75 HKD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
283.3 %
Dividend Yield
–
Gross Profit TTM
5 331 013 HKD
Earnings per share
–
Diluted Eps TTM
–
Most Recent Quarter
II 2023
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics 2179
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History 2179
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation 2179
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
–
Price Sales TTM
90.4721
Enterprise Value EBITDA
-14.8026
Price Book MRQ
4.332
Financials 2179
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators 2179
For 52 weeks
7.31 HKD
12.01 HKD
50 Day MA
8.56 HKD
Shares Short Prior Month
–
200 Day MA
8.72 HKD
Short Ratio
–
Shares Short
–
Short Percent
–
BeatStart